Home › Funds › NEXTBio Capital Management LP › ZBIO
NEXTBio Capital Management LP position in ZBIO
ZENAS BIOPHARMA INC · Health Care
NEXTBio Capital Management LP reported holding 426,736 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$11.5M, representing 5.01% of its reported portfolio and ranking #8 among its reported holdings. NEXTBio Capital Management LP has disclosed ZBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's ZBIO position evolved
NEXTBio Capital Management LP first disclosed a stake in ZBIO in Q4 2025 at 321,983 shares (US$11.7M). Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 426,736 shares valued at US$11.5M. Notable position changes include a 33% increase in Q1 2026 (shares rose 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 321.98K | $11.69M | New |
| Q1 2026 | 426.74K | $8.34M | Add |
| Q2 2026 | 426.74K | $10.83M | Hold |
| Q3 2026 | 426.74K | $11.51M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZBIO and 13F data
ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 62 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZBIO
- SR ONE CAPITAL MANAGEMENT, LP 5.04M sh · $127.86M · Q2 2026
- NEA Management Company, LLC 4.02M sh · $102.11M · Q2 2026
- Enavate Sciences GP, LLC 3.92M sh · $99.47M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M sh · $80.32M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 2.39M sh · $60.61M · Q2 2026
- Fairmount Funds Management LLC 2.36M sh · $59.87M · Q2 2026
- NVP Associates, LLC 1.84M sh · $46.66M · Q2 2026
- Context Capital Management, LLC 31.05M sh · $39.70M · Q3 2026
- EcoR1 Capital, LLC 789.50K sh · $20.04M · Q2 2026
- ArrowMark Colorado Holdings LLC 573.32K sh · $14.55M · Q2 2026
- Rock Springs Capital Management LP 502.08K sh · $12.74M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 490.77K sh · $12.46M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held ZBIO?
NEXTBio Capital Management LP has disclosed ZBIO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in ZBIO?
As of Q3 2026, NEXTBio Capital Management LP holds 426.74K shares of ZBIO (ZENAS BIOPHARMA INC), valued at $11.51M, representing 5.01% of its reported portfolio and ranking #8.
Has NEXTBio Capital Management LP been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in ZBIO.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.